Display options
Cite
Uehara T, Sumiyoshi T, Seo T, et al. T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period. ISRN Psychiatry. 2012;2012:947149doi: 10.5402/2012/947149.
Uehara, T., Sumiyoshi, T., Seo, T., Matsuoka, T., Itoh, H., & Kurachi, M. (2012). T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period. ISRN psychiatry, 2012947149. https://doi.org/10.5402/2012/947149
Uehara, Takashi, et al. "T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period." ISRN psychiatry vol. 2012 (2012): 947149. doi: https://doi.org/10.5402/2012/947149
Uehara T, Sumiyoshi T, Seo T, Matsuoka T, Itoh H, Kurachi M. T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period. ISRN Psychiatry. 2012 Jul 08;2012:947149. doi: 10.5402/2012/947149. Print 2012. PMID: 23738215; PMCID: PMC3658548.
Copy Download .nbib Format: NLM
Share it on

ISRN Psychiatry. 2012 Jul 08;2012:947149. doi: 10.5402/2012/947149. Print 2012.

T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period.

ISRN psychiatry

Takashi Uehara, Tomiki Sumiyoshi, Tomonori Seo, Tadasu Matsuoka, Hiroko Itoh, Masayoshi Kurachi

Affiliations

  1. Department of Neuropsychiatry, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan ; Division of Molecular and Clinical Neurobiology, Department of Psychiatry, Ludwig-Maximilians University of Munich, Nußbaumstraße 7, 80336 Munich, Germany.

PMID: 23738215 PMCID: PMC3658548 DOI: 10.5402/2012/947149

Abstract

The number of parvalbumin (PV)-positive γ -aminobutyric acid (GABA) neurons is decreased in the brain of rats transiently exposed to MK-801, an N-methyl-D-aspartate (NMDA) receptor blocker, in the neonatal stage (Uehara et al. (2012)). T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate] is a neuroprotective agent synthesized for the treatment of psychiatric disorders characterized by cognitive disturbances, such as dementia. We herein sought to determine whether T-817MA, haloperidol (HPD), or risperidone (RPD) would ameliorate the decrease in the number of PV-positive GABA neurons in the medial prefrontal cortex (mPFC) and hippocampus of the model animals. Rats were treated with MK-801 (0.2 mg/kg/day) or vehicle on postnatal days (PD) 7-10, and the number of PV-positive neurons in the mPFC and hippocampus were measured on PDs 63. T-817MA (20 mg/kg), HPD (1 mg/kg), or RPD (1 mg/kg) were administered during PDs 49-62. Fourteen-day administration of T-817MA reversed the decrease in the number of PV-positive neurons in the above brain regions of rats given MK-801, whereas HPD and RPD were ineffective. These results indicate that T-817MA provides a novel pharmacologic strategy to enhance cognitive function in patients with schizophrenia.

References

  1. Biol Psychiatry. 1999 Oct 1;46(7):871-81 - PubMed
  2. J Neurosci Res. 1999 Oct 1;58(1):152-66 - PubMed
  3. Pharmacol Rev. 2008 Sep;60(3):358-403 - PubMed
  4. Psychopharmacology (Berl). 2009 Nov;206(4):623-30 - PubMed
  5. Schizophr Res. 2002 May 1;55(1-2):1-10 - PubMed
  6. J Pharmacol Exp Ther. 2005 Jul;314(1):252-9 - PubMed
  7. J Neurochem. 1990 Mar;54(3):823-7 - PubMed
  8. Biol Psychiatry. 2001 Dec 1;50(11):884-97 - PubMed
  9. J Psychiatr Res. 2012 May;46(5):622-9 - PubMed
  10. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):846-58 - PubMed
  11. Synapse. 2012 May;66(5):408-17 - PubMed
  12. Biol Psychiatry. 2005 Feb 1;57(3):252-60 - PubMed
  13. Arch Gen Psychiatry. 1987 Jul;44(7):660-9 - PubMed
  14. Biol Psychiatry. 1999 Sep 15;46(6):729-39 - PubMed
  15. Schizophr Bull. 2009 May;35(3):528-48 - PubMed
  16. Schizophr Res. 1997 Apr 11;24(3):349-55 - PubMed
  17. Br J Pharmacol. 2009 Jun;157(3):451-63 - PubMed
  18. Mol Psychiatry. 2005 May;10(5):434-49 - PubMed
  19. N Engl J Med. 2003 Oct 30;349(18):1738-49 - PubMed
  20. Neuron. 2000 Nov;28(2):325-34 - PubMed
  21. Behav Brain Res. 2010 Mar 17;208(1):132-6 - PubMed
  22. Neurochem Int. 2006 Jan;48(2):124-30 - PubMed
  23. Psychopharmacology (Berl). 2008 Apr;197(3):457-64 - PubMed
  24. Biol Psychiatry. 2002 Oct 1;52(7):708-15 - PubMed
  25. Neuropsychopharmacology. 2001 Jul;25(1):1-27 - PubMed
  26. Schizophr Res. 2007 Dec;97(1-3):254-63 - PubMed
  27. Biol Psychiatry. 2011 May 15;69(10):953-8 - PubMed
  28. Front Synaptic Neurosci. 2011 May 17;3:3 - PubMed
  29. Hippocampus. 2007;17(6):443-55 - PubMed
  30. Biochem Biophys Res Commun. 2011 Apr 22;407(4):730-4 - PubMed
  31. Neuropharmacology. 2008 Oct;55(5):654-60 - PubMed
  32. Neuroscience. 2001;107(4):535-50 - PubMed
  33. Nat Rev Neurosci. 2005 Apr;6(4):312-24 - PubMed
  34. Eur J Biochem. 2000 Aug;267(16):4904-11 - PubMed
  35. Behav Brain Res. 2001 Nov 1;125(1-2):109-25 - PubMed
  36. J Clin Psychiatry. 2006 Jun;67(6):983-90 - PubMed
  37. Brain Res. 2010 Sep 17;1352:223-30 - PubMed

Publication Types